|
COPYRIGHT 2004 International Medical News Group
NEW YORK -- A novel peptide with immunosuppressive and antineoplastic properties may hold hope for reducing skin cancers in solid organ-transplant patients, Sarah B. Weitzul, M.D., said at the American Academy of Dermatology's Academy 2004 meeting.
Rapamycin, derived from a bacteria strain found in soil samples from Easter Island, has been shown to interfere with carcinogenic cellular mechanisms induced by exposure to UVB. Additionally, the peptide inhibits tumor cell growth in the laboratory and in animal models.
Even more promising are results of recent human trials, which consistently demonstrate lower rates of skin cancer in transplant recipients who receive rapamycin, often...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
